MedTrace Logo

Use of UC-MSCs for COVID-19 Patients

NCT04355728 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2021-12-06

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to learn about the safety and efficacy of human umbilical cord derived Mesenchymal Stem Cells (UC-MSC) for treatment of COVID-19 Patients with Severe Complications of Acute Lung Injury/Acute Respiratory Distress Syndrome (ALI/ARDS).

Conditions

  • Corona Virus Infection
  • ARDS
  • ARDS, Human
  • Acute Respiratory Distress Syndrome
  • COVID-19

Interventions

BIOLOGICAL

Umbilical Cord Mesenchymal Stem Cells + Heparin along with best supportive care.

UC-MSC will be administered at 100x10\^6 cells/infusion administered intravenously in addition to the standard of care treatment.

OTHER

Vehicle + Heparin along with best supportive care

Best supportive care treatment per the treating hospital protocol.

Sponsors & Collaborators

  • Camillo Ricordi

    lead OTHER

Principal Investigators

  • Camillo Ricordi, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-25
Primary Completion
2020-10-31
Completion
2020-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04355728 on ClinicalTrials.gov